Cargando…

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

BACKGROUND: (131)I-metaiodobenzylguanidine (MIBG) is an active radiopharmaceutical in neuroblastoma. A previous study demonstrated that MIBG could be combined with vincristine and prolonged irinotecan, although 25% of first courses had grade 3 diarrhoea. The current phase I/II study evaluated MIBG w...

Descripción completa

Detalles Bibliográficos
Autores principales:	DuBois, S G, Allen, S, Bent, M, Hilton, J F, Hollinger, F, Hawkins, R, Courtier, J, Mosse, Y P, Matthay, K K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333502/ https://www.ncbi.nlm.nih.gov/pubmed/25602966 http://dx.doi.org/10.1038/bjc.2015.12

Ejemplares similares

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
por: Vaidyanathan, G., et al.
Publicado: (1996)

Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2017)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA(®)) in Patients with Iobenguane Scan Positive Cancers
por: Jimenez, Camilo, et al.
Publicado: (2019)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Metastatic Pheochromocytoma Diagnosed with (131) I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation
por: Vankadari, Kousik, et al.
Publicado: (2022)

Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
por: Brady, Samuel L., et al.
Publicado: (2019)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
por: Venkatramani, Rajkumar, et al.
Publicado: (2013)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
por: Lewington, V., et al.
Publicado: (2016)

Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy: A Case Report
por: Cai, Yi, et al.
Publicado: (2015)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Comparison Between Diffusion‐Weighted MRI and (123)I‐mIBG Uptake in Primary High‐Risk Neuroblastoma
por: Privitera, Laura, et al.
Publicado: (2020)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
por: Calvet, L, et al.
Publicado: (2004)

(123)I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
por: Kitamura, Yoshiyuki, et al.
Publicado: (2021)

The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997)

Malignant paragangliomas with succinate dehydrogenase subunit B mutation in a 13-year old child treated successfully with surgery and 131-I-MIBG
por: Chow, Chi Kwan Jasmine, et al.
Publicado: (2013)

Recurrent malignant pheochromocytoma with unusual omental metastasis: (68)Ga-DOTANOC PET/CT and (131)I-MIBG SPECT/CT scintigraphy findings
por: Arora, Saurabh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_titfpacr0b8e8u1ltdsk71uapi